4Linton HJ, Marks LS, Millar LS, et al.Benign prostate-specific antigen(BPSA) in serum is increased in benign prostate disease [ J ]. Clin Chem,2003,49(2) :253.
5Mikolajczyk SD, Rittenhouse HG,Tumor-associated forms of prostate specific antigen improve the discrimination of prostate cancer from benign disease[J]. Rinsho Byori,2004,52(3) :223.
6Barkin J, Grumaraes M, Jacobi G, et al. Alpha-blocker therapy can be with-drawn in the majority of men following initial combination therapy with the dual 5alpha-reductase inhibitor dutasteride[J]. Eur Urol, 2003,44(4) :461.
7O'Leary MP, Roehrborn C, Andriole G,et al. Improvements in benign prostatic hyperplasia-specific quality of life with dutasteride, the novel dual 5 alpha-reductase inhibitor [ J ]. BJU Int, 2003,92(3) :262.
8Shapiro E, Hartanto V, Lepor H. Quantifying the smooth muscle content of the prostate using double immunoenzymaticstaining and color assisted image analysis[J]. J Urol, 1992, 147(4): 1167.
9Oesterling JE. Benign prostatic hyperplasia, medical and minimally invasive treatment options [ J ]. N Eng J Med,1995,332 (2) :99.
10Rodrigues P,Lucon AM,Freire GC,at al.Urodynamic pressure flow studies can predict the clinical outcome after transurethral prostatic resection.J Urol,2001,165:499-502.
9McNeill SA. The iole of alpha - blockers in the maragement of acute ufinery retention caused by benigrc prostatic obstruction. Eur Urol, 2004,45 ( 3 ) :325 - 332.
10McConnell JD, Roehrbom CG, Bautista OM, et al. The long - term effect of doxazosin, finasteride, and combination therapy on the clini- cal progression of benign prostatic hyperplasia. N Engl J Med, 2003, 349:2387 - 2398.
